Hydroxyprogesterone Caproate
drugOn this page
Also known as 17.alpha.-caproyloxy-p417.alpha.-hydroxyprogesterone17alpha-hydroxyprogesteroneCaproate d'hydroxyprogesteroneCaproato de hidroxiprogesteronaDelalutinDepo-prolutonHidroxiprogesteronaHormofortHydroxyprogesteroneHydroxyprogesterone hexanoateHylutinMakenaMakena (autoinjector)Makena preservative freeNSC-15468NSC-17592PharlonPrimolut depot
Summary
Hydroxyprogesterone Caproate (CHEMBL1200848) is an approved small molecule (ATC G03DA03); indicated across 2 conditions.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: G03DA03
- Indications: 2 conditions
- Clinical trials: 8
- Chemistry: 428.6 Da · C27H40O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200848 |
| Name | Hydroxyprogesterone Caproate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 169870 |
| ATC | G03DA03 |
| Molecular formula | C27H40O4 |
| Molecular weight | 428.6 |
| InChIKey | DOMWKUIIPQCAJU-LJHIYBGHSA-N |
SMILES: CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C
IUPAC name: [(8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate
Also known as: 17.alpha.-caproyloxy-p4, 17.alpha.-hydroxyprogesterone, 17alpha-hydroxyprogesterone, Caproate d’hydroxyprogesterone, Caproato de hidroxiprogesterona, Delalutin, Depo-proluton, Hidroxiprogesterona, Hormofort, Hydroxyprogesterone, Hydroxyprogesterone caproate, Hydroxyprogesterone hexanoate
Parent form; salt/anhydrous children: CHEMBL3526451
Patent coverage: 4,264 distinct patent families (16,548 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 21 (assay-derived). Sample: Microtubule-associated protein tau, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Ferritin light chain, Protein RecA, Replicative DNA helicase DnaB, Glucocorticoid receptor, Progesterone receptor.
Bioactivity
ChEMBL activities: 10 potent at pChembl ≥ 5 of 23 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| PGR | 8.52 | AC50 | 3 | nM | CHEMBL_ACT_25223413 |
| NR3C1 | 8.15 | AC50 | 7 | nM | CHEMBL_ACT_25176284 |
| P15207 | 6.01 | AC50 | 980 | nM | CHEMBL_ACT_25187710 |
| NR1I2 | 5.77 | AC50 | 1703 | nM | CHEMBL_ACT_25188524 |
| P9WMR3 | 5.69 | AC50 | 2023 | nM | CHEMBL_ACT_7391870 |
| HIF1A | 5.4 | Potency | 3981 | nM | CHEMBL_ACT_4127974 |
| HIF1A | 5.4 | Potency | 3981 | nM | CHEMBL_ACT_4520583 |
| P9WHJ3 | 5.31 | EC50 | 4880 | nM | CHEMBL_ACT_6773008 |
| HTT | 5 | Potency | 10000 | nM | CHEMBL_ACT_3753855 |
| NPSR1 | 5 | Potency | 10000 | nM | CHEMBL_ACT_4929347 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (1 at ChEMBL trial phase 4).
The 2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 8.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| Not specified | 2 |
| PHASE4 | 1 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04797338 | PHASE4 | UNKNOWN | Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders |
| NCT03433040 | PHASE3 | COMPLETED | 17OHP-C Dosing Among Obese Pregnant Women |
| NCT00409825 | PHASE2 | COMPLETED | Study of Pharmacology of 17-OHPC in Pregnancy |
| NCT01050647 | PHASE1/PHASE2 | COMPLETED | Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial. |
| NCT04807543 | PHASE2 | COMPLETED | Effect of Progesterone on Latent Phase Prolongation in Patients With Preterm Premature Rupture of Membranes |
| NCT01899846 | PHASE1 | COMPLETED | Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood |
| NCT03779438 | Not specified | UNKNOWN | 17-Alpha-Hydroxyprogesterone Caproate in Pregnant Women With Placenta Previa |
| NCT03779451 | Not specified | UNKNOWN | Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate in Placenta Previa |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.